TABLE 1

Insulin secretion characteristics based on deconvolution analysis and regularity analysis during basal conditions, acute stimulation, and 5-week treatment with placebo and gliclazide

Placebo
Gliclazide
BasalAcute5 Weeks5 Weeks-elevatedBasalAcute5 Weeks5 Weeks-elevated
Deconvolution analysis
 Secretory burst mass (pmol · l−1 · pulse−1)36.1 ± 8.430.3 ± 7.442.4 ± 12.837.1 ± 9.543.0 ± 12.061.0 ± 17.0*34.8 ± 9.749.7 ± 13.3*
 Secretory burst amplitude (pmol · l−1 · min−1)14.4 ± 3.312.1 ± 2.916.8 ± 5.014.8 ± 3.817.1 ± 4.824.3 ± 6.8*13.9 ± 3.919.8 ± 5.3*
 Basal secretion (pmol · l−1 · min−1)5.9 ± 0.97.2 ± 1.16.8 ± 1.59.4 ± 2.18.5 ± 2.216.7 ± 4.3*8.8 ± 2.1*12.2 ± 2.5*
 Interpulse interval (min/pulse)6.7 ± 0.56.9 ± 0.77.1 ± 1.26.4 ± 0.55.9 ± 0.55.9 ± 0.46.5 ± 0.45.2 ± 0.4*
Regularity analysis
 Autocorrelation coefficient0.16 ± 0.020.15 ± 0.030.24 ± 0.030.24 ± 0.030.25 ± 0.040.22 ± 0.030.18 ± 0.030.21 ± 0.03
 Spectral power8.5 ± 0.77.5 ± 0.910.2 ± 0.99.4 ± 0.99.2 ± 1.09.6 ± 1.17.6 ± 0.8*9.0 ± 0.9
 Frequency (min/pulse)6.9 ± 0.55.7 ± 0.46.7 ± 0.46.7 ± 0.47.0 ± 0.56.7 ± 0.37.1 ± 0.46.1 ± 0.5
 ApEn (r = 0.2 × SD, m = 1)1.496 ± 0.0331.464 ± 0.0161.505 ± 0.0281.506 ± 0.0231.482 ± 0.0291.514 ± 0.0271.483 ± 0.0181.524 ± 0.019
 ApEn (r = 1.0 × SD, m = 1)0.642 ± 0.0260.638 ± 0.0270.662 ± 0.0230.664 ± 0.0190.639 ± 0.0430.662 ± 0.0250.631 ± 0.0260.663 ± 0.027
  • Data are means ± SE.

  • *

    * P < 0.05, testing for treatment effect (gliclazide vs. placebo) in the crossover model.